Furthermore, an IgE-specific nanobody with a KD = 1.4 nM revealed to bind free IgE with a higher potency than Omalizumab, an observation exemplifying the importance of the high affinity of biologics useful for allergy treatment [79]. This evidence concerns the gene IGHE and allergic disease.